S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 5, 2011, Pages 777-784

  Rohde, David ^a   Brinks, Henriette ^b   Ritterhoff, Julia ^a   Qui, Gang ^c   Ren, Shumei ^c   Most, Patrick ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Calcium; Gene therapy; Heart failure; Mitochondria; Myofilaments; Reticulum; S100A1; Sarcoplasmic

Indexed keywords

CALCIUM ION; METOPROLOL; PARVOVIRUS VECTOR; PROTEIN S 100; PROTEIN S100A1; UNCLASSIFIED DRUG;

CELL DEATH; CELL SURVIVAL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENERGY METABOLISM; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE THERAPY; HEART FAILURE; HEART MUSCLE EXCITABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ENERGY METABOLISM; GENE THERAPY; HEART FAILURE; HUMANS; S100 PROTEINS;

EID: 79953693561     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.08.012     Document Type: Review

References (49)

1. AHA Heart disease and stroke statistics - 2010 update. Circulation 2010, 121:e1-e170.
2. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
3. Vinge L.E., Raake P.W., Koch W.J. Gene therapy in heart failure. Circ Res 2008, 102(12):1458-1470.
4. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008, 70:23-49.
5. Houser S.R., Margulies K.B. Is depressed myocyte contractility centrally involved in heart failure?. Circ Res 2003, 92(4):350-358.
6. Hajjar R.J., del Monte F., Matsui T., Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000, 86(6):616-621.
7. Hajjar R.J., Zsebo K., Deckelbaum L., Thompson C., Rudy J., Yaroshinsky A., et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008, 14(5):355-367.
8. Kraus C., Rohde D., Weidenhammer C., Qiu G., Pleger S.T., Voelkers M., et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009, 47(4):445-455.
9. Most P., Remppis A., Pleger S.T., Katus H.A., Koch W.J. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007, 293(2):R568-R577.
10. Voelkers M., Rohde D., Goodman C., Most P. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol 2010, 178614.
11. Most P., Koch W.J. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol 2007, 3:5-11.
12. Wright N.T., Cannon B.R., Zimmer D.B., Weber D.J. S100A1: structure, function, and therapeutic potential. Curr Chem Biol 2009, 3(2):138-145.
13. Remppis A., Greten T., Schafer B.W., Hunziker P., Erne P., Katus H.A., et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996, 1313(3):253-257.
14. Desjardins J.F., Pourdjabbar A., Quan A., Leong-Poi H., Teichert-Kuliszewska K., Verma S., et al. Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction. Am J Physiol Heart Circ Physiol 2009, 296(5):H1457-H1465.
15. Most P., Pleger S.T., Völkers M., Heidt B., Boerries M., Weichenhan D., et al. Cardiac adenoviral S100A1 gene transfer rescues failing myocardium. J Clin Investig 2004, 114:1550-1563.
16. Most P., Seifert H., Gao E., Funakoshi H., Volkers M., Heierhorst J., et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 2006, 114(12):1258-1268.
17. Tsoporis J.N., Marks A., Zimmer D.B., McMahon C., Parker T.G. The myocardial protein S100A1 plays a role in the maintenance of normal gene expression in the adult heart. Mol Cell Biochem 2003, 242(1-2):27-33.
18. Gupta R.C., Mishra S., Rastogi S., Wang M., Rousso B., Mika Y., et al. Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals. Clin Transl Sci 2009, 2(3):211-215.
19. Pleger S.T., Shan C., Kziencek J., Mueller O., Bekereddjian R., Remppis A., et al. Retroinfusion-facilitated inotropic AAV9-S100A1 gene therapy restores global cardiac function in a clinically relevant pig heart failure model. Circulation 2008, 118:S_792.
20. Kiewitz R., Lyons G.E., Schafer B.W., Heizmann C.W. Transcriptional regulation of S100A1 and expression during mouse heart development. Biochim Biophys Acta 2000, 1498(2-3):207-219.
21. Boerries M., Most P., Gledhill J.R., Walker J.E., Katus H.A., Koch W.J., et al. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007, 27(12):4365-4373.
22. Most P., Bernotat J., Ehlermann P., Pleger S.T., Reppel M., Borries M., et al. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA 2001, 98(24):13889-13894.
23. Most P., Eicher C., Börries M., Schweda C., Völkers M., Wedel T., et al. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci 2005, 118:421-431.
24. Remppis A., Most P., Löffler E., Ehlermann P., Bernotat J., Pleger S.T., et al. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol 2002, 97(Suppl.1):I/56-I/62.
25. Remppis A., Pleger S.T., Most P., Lindenkamp J., Ehlermann P., Löffler E., et al. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med 2004, 6:387-394.
26. Most P., Remppis A., Pleger S.T., Löffler E., Ehlermann P., Bernotat J., et al. Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 2003, 278(5):33809-33817.
27. Volkers M., Loughrey C.M., Macquaide N., Remppis A., DeGeorge B.R., Wegner F.V., et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2007, 41(2):135-143.
28. Voelkers M., Weidenhammer C., Herzog N., Friedrich O., Fink R.H.A., Koch W.J., et al. S100A1 prevents arrythmogenic diastolic sarcoplasmic reticulum calcium leak in ventricular cardiomyocytes. Circulation 2008, 118:S_527.
29. Kettlewell S., Most P., Currie S., Koch H., Smith G.L. S100A1 increases the gain of excitation- coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol 2005, 39:900-910.
30. Most P., Remppis A., Weber C., Bernotat J., Ehlermann P., Pleger S.T., et al. The C-terminus (aa 75-94) and the linker region (aa 42-54) of the Ca2+ binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibres. J Biol Chem 2003, 278(29):26356-26364.
31. Treves S., Scutari E., Robert M., Groh S., Ottolia M., Prestipino G., et al. Interaction of S100A1 with the Ca2+ release channel (ryanodine receptor) of skeletal muscle. Biochemistry 1997, 36(38):11496-11503.
32. Wright N.T., Prosser B.L., Varney K.M., Zimmer D.B., Schneider M.F., Weber D.J. S100A1 and calmodulin compete for the same binding site on ryanodine receptor. J Biol Chem 2008, 283(39):26676-26683.
33. Kiewitz R., Acklin C., Schafer B.W., Maco B., Uhri K.B., Wuytack F., et al. Ca(2+)-dependent interaction of S100A1 with the sarcoplasmic reticulum Ca(2+)-ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun 2003, 306(2):550-557.
34. Wright N.T., Varney K.M., Karen C.E., Markowitz J., Rossitza K.G., Zimmer D.B., et al. The three-dimensional solution structure of Ca2+-bound S100A1 as determined by NMR spectroscopy. J Mol Biol 2005, 353:410-426.
35. Yamasaki R., Berri M., Wu Y., Trombitas K., McNabb M., Kellermayer M.S., et al. Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/s100a1. Biophys J 2001, 81(4):2297-2313.
36. Fukushima H., Chung C., Granzier H. Titin-isoform dependence of titin-actin interaction and its regulation by S100A1/Ca2+ in skinned myocardium. J Biomed Biotechnol 2010, 2010:727239 [published online].
37. LeWinter M.M., Granzier H. Cardiac titin: a multifunctional giant. Circulation 2010, 121(19):2137-2145.
38. Maco B., Mandinova A., Durrenberger M.B., Schafer B.W., Uhrik K.B., Heizmann C.W. Ultrastructural distribution of the S100A1 Ca2+-binding protein in the human heart. Physiol Res 2001, 50:567-574.
39. Most P., Zeitz O., Janssen P.M.L., Ehlermann P., Reppel M., Hasenfuss G., et al. S100A1 modulates Ca2+ sensitivity of cardiac myofilaments. Eur Heart J 2000, 21:60. Suppl.
40. Brezova A., Heizmann C.W., Uhrik B. Immunocytochemical localization of S100A1 in mitochondria on cryosections of the rat heart. Gen Physiol Biophys 2007, 26(2):143-149.
41. Ackermann G.E., Domenighetti A.A., Deten A., Bonath I., Marenholz I., Pedrazzini T., et al. S100A1 deficiency results in prolonged ventricular repolarization in response to sympathetic activation. Gen Physiol Biophys 2008, 27(2):127-142.
42. Du X.J., Cole T.J., Tenis N., Gao X.M., Kontgen F., Kemp B.E., et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol 2002, 22(8):2821-2829.
43. Gusev K., Ackermann G.E., Heizmann C.W., Niggli E. Ca(2+) signaling in mouse cardiomyocytes with ablated S100A1 protein. Gen Physiol Biophys 2009, 28(4):371-383.
44. Pleger S.T., Most P., Boucher M., Soltys S., Chuprun J.K., Pleger W., et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007, 115(19):2506-2515.
45. Pleger S.T., Most P., Heidt B., Voelkers M., Hata J.A., Katus H.A., et al. S100A1 gene transfer in myocardium. Eur J Med Res 2006, 11(10):418-422.
46. Pleger S.T., Remppis A., Heidt B., Völkers M., Chaprun J.K., Kuhn M., et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther 2005, 12:1120-1129.
47. Rudy Y., Ackerman M.J., Bers D.M., Clancy C.E., Houser S.R., London B., et al. Systems approach to understanding electromechanical activity in the human heart: a national heart, lung, and blood institute workshop summary. Circulation 2008, 118(11):1202-1211.
48. Dixon J.A., Spinale F.G. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009, 2(3):262-271.
49. Weller M.L., Amornphimoltham P., Schmidt M., Wilson P.A., Gutkind J.S., Chiorini J.A. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 2010, 16:662-664.